Connect with us

Health Care

Exopharm Ltd (ASX:EX1) – Christopher Baldwin

Published

on

The CEO Mindset - Christopher Baldwin is the Chief Commercial Officer at Exopharm Ltd (ASX:EX1)

Christopher Baldwin is the Chief Commercial Officer at Exopharm Ltd (ASX:EX1), an Australian regenerative medicine biopharmaceutical company that is seeking to develop and commercialise exosomes as therapeutic agents – initially a product called Plexaris™ and later a product called Cevaris™.

What’s your journey in becoming a CEO?
In my case, that’s still a work in progress! I see the journey as one from processes, to products, to people. As a chemical engineer and later as a consultant at McKinsey, I was most concerned with how complex systems functioned (or didn’t), how to diagnose them analytically, and how to move into better operations. I followed this with 10 years working across Asia Pacific leading commercial activities with hospitals and blood services. This is where I really learned the critical importance of well-designed, reliable products and how their value manifests in extremely diverse environments. Now, in the senior leadership at Exopharm, it strikes me every day how important people are. Helping them on their own journeys, keeping them engaged and pulling together, this becomes the true enabler of success.

Tell us a bit about your business and how you are commercializing?
We are on the cutting edge of a new biotechnology, the creation of medicines based on exosomes. Exosomes are the primary cell-to-cell communication network in the body, passing proteins, growth factors, and nucleic acids to orchestrate healing and repair. Our founding technology solved the challenge of isolating and purifying exosomes from blood and cell media. We are using this core technology to develop applications for a variety of diseases.

How are you managing with the current COVID-19 pandemic on both business and personal front?
This has been an extraordinary time. It has created considerable business disruption, of course, but once the noise settled, I found that it created a natural pause that allowed us to really take stock of where we were as a company and where we wanted to head. I would say we are more clear-minded, more ambitious, and have more opportunities than before. One example of this is Fortrexo COV, our approach to interrupting the progression of a coronavirus infection. This project has us excited and focused to apply the capabilities we have been assembling. Personally, I am grateful that family and close friends have not been seriously affected.

What’s the most exciting thing about running your business?
I find interacting with talented and committed people incredibly rewarding, and Exopharm is full of them! From our scientists to our business partners to our investors, we are surrounded by youthful geniuses, dedicated experts, and seasoned polymaths and entrepreneurs. Their curiosity and enthusiasm are infectious.

How do you measure success?
Genuine success only happens over years. Have we improved people’s lives, reduced their suffering, enabled their ambitions? From this perspective, genuine success is truly immeasurable. Of course, annual reports to shareholders would be quite slim if we insisted on measuring just that. For a company such as ours, success is best measured in the important milestones on the way to our objectives: clinical results, partnerships, patents and eventually, sales.

What do you think is the most important quality of being a CEO of a listed company?
Clarity. The world is full of opportunities, but not every opportunity is interesting for every investor or every employee. We have to be clear what we are trying to accomplish and how, so that each person can decide if they want to participate. Whether people are committing capital, time in their careers, or both to our company’s mission, it is important that they understand their choices as clearly as possible, and ultimately, that responsibility for clarity sits with the CEO.

What is your favourite book?
Cryptonomicon by Neal Stephenson, or just about anything else he’s written.

What message do you want to send to our readership in Asia?
Spend some time learning about exosomes – they weren’t in textbooks when you were in school, but they’ve been busy growing and repairing your body your entire life. They are truly fascinating and I think they will become very important to healthcare in the years to come.

How can people connect with you?
Email: chris.baldwin@exopharm.com
Company Website: https://exopharm.com/

Want to be on the list next time this company raises capital? Open an account with Fresh Equities and start exploring capital raises – freshequities.com

Health Care

mPort and Springday – Dipra Ray

Published

on

The CEO Mindset - Dipra Ray, CEO of mPort and Springday

Dipra Ray is the CEO of mPort and Springday, the former being a health company specialising in 3D body mapping, to assist people on their wellbeing journeys while the latter is a corporate wellbeing organisation that develops bespoke programs for workplaces to keep their employees happy and engaged in their roles. The companies merged together at the end of 2019. 

What’s your journey in becoming a Chief Executive Officer?
I started my first business when I was in high school where I managed a network of really intelligent people who worked as tutors which gave me a strong foundation in being able to both hire and manage exceptional people. At university, I decided to pursue studies in Accounting and Finance as I thought would provide me with the base knowledge of how businesses operated and ended up completing an Honours in Finance. Post my Honours, I started my career as an investment banker with Deutsche Bank specialising in mergers and acquisitions. This gave me a broad base of commercial & capital markets knowledge and also the ability to work under high pressure environments. Post my stint at Deutsche, I founded mPort and was the first CEO there and have continued in that role since.

Tell us a bit about your business and how you are commercializing?
mPort and Springday are building clever ecosystems that help to improve the wellbeing of people. At mPort we do this via capturing accurate body measurements through our one-of-a-kind fully automated mPods that are located in most of Australia’s top shopping centres. People use our service to see how their bodies are changing over time and to keep themselves motivated on their fitness journey. Springday on the other hand provides corporates with a platform to help keep their staff engaged, happier and healthier. We work with businesses to build wellbeing journeys that are personalised, interesting and fun. We work with some of Australia’s leading businesses who are committed to improve the wellbeing of their people.

What’s the most exciting thing about running your business?
The most exciting part about running mPort & Springday is that we’re constantly growing and expanding both our products but also the range of industries and clients we service. Every week is an ability for us to continue building our product and create more value for our partners and customers. It’s also super exciting to see how we’ve been able to mature as a business and see the level of growth we’re generating for our own people.

How do you measure success?
Success = being happy 🙂

What do you think is the most important quality of being a CEO of a listed company?
The most important quality of being a CEO is to be able to set an achievable focused strategic vision and then focus ruthlessly on execution. Too many businesses set far too broad strategic visions or stumble when it comes to execution by getting distracted by anything new. Being disciplined and focused on one’s core strategies is really important for a high growth business.

What is your favourite book?
Liar’s Poker by Michael Lewis and Five Point Someone by Chetan Bhagat.

What message do you want to send to our readership in Asia & Australia?
Health and wellbeing will develop into a more sophisticated trend that what we’ve seen in the past few years. So far, the trend has been mainly focused on products such as health foods, dairy and alike. We’re seeing that shift as consumers become more aware of how important overall wellbeing is – both from an emotional and physical perspective. While emotional wellbeing still remains a taboo topic in a lot of Asian countries that will change as the younger generation demands better conditions and as the global workforce becomes more mobile. This is primarily why we see a huge opportunity to invest in wellbeing in the Asian markets.

How can people connect with you?
Linkedin: https://www.linkedin.com/in/dipra-ray/
mPort’s Website: https://mport.com/
Springday’s Website: https://myspringday.com.au/

Continue Reading

Health Care

Q&A With StockPal – Race Oncology (ASX:RAC)

Published

on

Q&A with StockPal - Dr. Daniel Tillett, Chief Scientific Officer (CSO) & Executive Director of Race Oncology (ASX:RAC)

Watch Dr. Daniel Tillett, Chief Scientific Officer (CSO) & Executive Director of Race Oncology (ASX:RAC), as he discusses the latest Israel AML Phase 2 Trial recently and the commencement of the Phase 2 Extramedullary AML Trial.

0:15 – Could you walk us through the latest announcement with regards to the Israel AML Phase 2 Trial Contract?
1:59 – Any reason for choosing Israel as the trial candidate, and which other countries were considered?
3:11 – When do you foresee Phase 3 to commence and what milestones must be achieved first?
5:16 – Lastly, could you also comment on the Phase 2 Extramedullary AML Trial commencement?

Visit RAC’s website to learn more about their story: https://www.raceoncology.com/

Email editor@stockpal.asia if you are or represent a listed-company and is keen to be in our interviews.

Want to be on the list next time this company raises capital? Open an account with Fresh Equities and start exploring capital raises – freshequities.com

Continue Reading

Health Care

Q&A With StockPal – Exopharm (ASX:EX1)

Published

on

Q&A with StockPal - Chris Baldwin, Deputy CEO of Exopharm (ASX:EX1)

Watch Chris Baldwin, Deputy CEO of Exopharm (ASX:EX1), as he explains about the Exopharm’s latest developments and potential target markets.

0:00 – Intro

0:10 – What is your business about?

1:20 – Tell us about your product developments and pipeline?

3:01 – What is the size of your potential target markets?

4:16 – What is EX1’s competitive advantage?

5:30 – How did your company cope during the COVID-19 pandemic?

6:28 – How are you currently engaging with your investors?

Visit Exopharm’s website: https://exopharm.com/

Email editor@stockpal.asia if you are or represent a listed-company and is keen to be in our interviews.

Want to be on the list next time this company raises capital? Open an account with Fresh Equities and start exploring capital raises – freshequities.com

Continue Reading

Get more stuff

Subscribe to our mailing list and get interesting stuff and updates to your email inbox.

Recent Posts

Categories

Trending